Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1317–1320. doi: 10.1128/aac.40.5.1317

Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.

F Barchiesi 1, L K Najvar 1, M F Luther 1, G Scalise 1, M G Rinaldi 1, J R Graybill 1
PMCID: PMC163320  PMID: 8723495

Abstract

Four strains of Candida albicans, isolated from two patients with AIDS who had undergone prolonged fluconazole therapy for oral candidiasis, were studied in a model of disseminated murine candidiasis. Pre- and posttreatment isolates from each patient were genetically related, and the fluconazole MICs for the strains had increased significantly, from 0.25 to 32 micrograms/ml for the strains isolated from patient 1 and from 1.0 to 16 micrograms/ml for the strains isolated from patient 2. Mice were infected intravenously and were treated orally with fluconazole. For survival studies, mice were treated from day 1 to day 10 postinfection and were observed through day 30. The fluconazole dosages were as follows: 0.25, 0.5, 1.0, and 5.0 mg/kg of body weight twice a day. For tissue burden studies, two groups of mice (each group received fluconazole at 0.25 or 5.0 mg/kg) were treated from day 1 to day 7 and were sacrificed 1 day later for quantitative tissue cultures of the spleen and both kidneys. For pretreatment isolates from both patients, all fluconazole dosing regimens were effective at prolonging survival compared with the survival of the control groups. For posttreatment isolates, only fluconazole at 5.0 mg/kg was effective at prolonging survival. Both fluconazole dosing regimens used in the tissue burden studies significantly reduced the counts of the pretreatment isolate from patient 1 in the spleen and kidney, while fluconazole at 5.0 mg/kg was effective at reducing the counts of the posttreatment isolate. For both isolates from patient 2, only fluconazole at 5.0 mg/kg was effective at reducing the counts in the spleen and kidney. The study indicates that C. albicans mutation to resistance to fluconazole may play a critical role in fluconazole-refractory oral candidiasis in AIDS patients.

Full Text

The Full Text of this article is available as a PDF (198.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barchiesi F., Hollis R. J., Del Poeta M., McGough D. A., Scalise G., Rinaldi M. G., Pfaller M. A. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin Infect Dis. 1995 Sep;21(3):561–564. doi: 10.1093/clinids/21.3.561. [DOI] [PubMed] [Google Scholar]
  2. Barchiesi F., Hollis R. J., McGough D. A., Scalise G., Rinaldi M. G., Pfaller M. A. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis. 1995 Mar;20(3):634–640. doi: 10.1093/clinids/20.3.634. [DOI] [PubMed] [Google Scholar]
  3. Bart-Delabesse E., Boiron P., Carlotti A., Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 1993 Nov;31(11):2933–2937. doi: 10.1128/jcm.31.11.2933-2937.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boken D. J., Swindells S., Rinaldi M. G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993 Dec;17(6):1018–1021. doi: 10.1093/clinids/17.6.1018. [DOI] [PubMed] [Google Scholar]
  5. Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Garcia-Hermoso D., Dromer F., Improvisi L., Provost F., Dupont B. Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob Agents Chemother. 1995 Mar;39(3):656–660. doi: 10.1128/AAC.39.3.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goff D. A., Koletar S. L., Buesching W. J., Barnishan J., Fass R. J. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis. 1995 Jan;20(1):77–83. doi: 10.1093/clinids/20.1.77. [DOI] [PubMed] [Google Scholar]
  8. He X., Tiballi R. N., Zarins L. T., Bradley S. F., Sangeorzan J. A., Kauffman C. A. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994 Oct;38(10):2495–2497. doi: 10.1128/aac.38.10.2495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hennequin C., Labenne M., Benkerrou M., Hambourg M. Fluconazole-resistant Candida albicans in an immunocompetent child. Clin Infect Dis. 1994 Dec;19(6):1179–1180. doi: 10.1093/clinids/19.6.1179. [DOI] [PubMed] [Google Scholar]
  10. Imam N., Carpenter C. C., Mayer K. H., Fisher A., Stein M., Danforth S. B. Hierarchical pattern of mucosal candida infections in HIV-seropositive women. Am J Med. 1990 Aug;89(2):142–146. doi: 10.1016/0002-9343(90)90291-k. [DOI] [PubMed] [Google Scholar]
  11. Johnson E. M., Warnock D. W., Luker J., Porter S. R., Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother. 1995 Jan;35(1):103–114. doi: 10.1093/jac/35.1.103. [DOI] [PubMed] [Google Scholar]
  12. Klein R. S., Harris C. A., Small C. B., Moll B., Lesser M., Friedland G. H. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984 Aug 9;311(6):354–358. doi: 10.1056/NEJM198408093110602. [DOI] [PubMed] [Google Scholar]
  13. Lyman C. A., Walsh T. J. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs. 1992 Jul;44(1):9–35. doi: 10.2165/00003495-199244010-00002. [DOI] [PubMed] [Google Scholar]
  14. Millon L., Manteaux A., Reboux G., Drobacheff C., Monod M., Barale T., Michel-Briand Y. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol. 1994 Apr;32(4):1115–1118. doi: 10.1128/jcm.32.4.1115-1118.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  16. Pfaller M. A., Rhine-Chalberg J., Redding S. W., Smith J., Farinacci G., Fothergill A. W., Rinaldi M. G. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 1994 Jan;32(1):59–64. doi: 10.1128/jcm.32.1.59-64.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Powderly W. G., Robinson K., Keath E. J. Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. J Infect Dis. 1993 Aug;168(2):463–466. doi: 10.1093/infdis/168.2.463. [DOI] [PubMed] [Google Scholar]
  18. Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Rhine-Chalberg J., Pfaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994 Feb;18(2):240–242. doi: 10.1093/clinids/18.2.240. [DOI] [PubMed] [Google Scholar]
  19. Rex J. H., Rinaldi M. G., Pfaller M. A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1–8. doi: 10.1128/aac.39.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Reynes J., Mallie M., Ravisse P., Bastide J. M. Activity of fluconazole against Candida albicans isolates from HIV+ patients in a digestive candidosis turkey model. J Med Vet Mycol. 1992;30(5):363–367. [PubMed] [Google Scholar]
  21. Rodríguez-Tudela J. L., Martínez-Suárez J. V., Dronda F., Laguna F., Chaves F., Valencia E. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J Antimicrob Chemother. 1995 Jun;35(6):793–804. doi: 10.1093/jac/35.6.793. [DOI] [PubMed] [Google Scholar]
  22. Ruhnke M., Eigler A., Tennagen I., Geiseler B., Engelmann E., Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol. 1994 Sep;32(9):2092–2098. doi: 10.1128/jcm.32.9.2092-2098.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  24. Sandven P., Bjørneklett A., Maeland A. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother. 1993 Nov;37(11):2443–2448. doi: 10.1128/aac.37.11.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smith K. J., Warnock D. W., Kennedy C. T., Johnson E. M., Hopwood V., Van Cutsem J., Vanden Bossche H. Azole resistance in Candida albicans. J Med Vet Mycol. 1986 Apr;24(2):133–144. [PubMed] [Google Scholar]
  26. Troillet N., Durussel C., Bille J., Glauser M. P., Chave J. P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1993 Dec;12(12):911–915. doi: 10.1007/BF01992164. [DOI] [PubMed] [Google Scholar]
  27. Velez J. D., Allendoerfer R., Luther M., Rinaldi M. G., Graybill J. R. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis. 1993 Aug;168(2):508–510. doi: 10.1093/infdis/168.2.508. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES